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ABSTRACT The aim of this study was to develop a measure of the impact of pulmonary hypertension
(PH) on health-related quality of life (HRQoL) as there is a need for a short, validated instrument that can
be used in routine clinical practice.
Interviews were conducted with 30 PH patients to derive 32 statements, which were presented as a
semantic differential six-point scale (0–5), with contrasting adjectives at each end. This item list was
completed by patients attending PH clinics across the UK and Ireland. Rasch analysis was applied to identify
items fitting a uni-dimensional model.
226 patients (mean age 55.6¡14 years; 70% female) with PH (82% had pulmonary arterial hypertension)
completed the study questionnaires. 10 of the 32 items demonstrated fit to the Rasch model (Chi-squared
16; p.0.05) and generated the emPHasis-10 questionnaire. Test–retest (intraclass correlation coefficient
0.95, n533) and internal consistency (Chronbach’s a50.9) were strong. emPHasis-10 scores correlated
consistently with other relevant measures and discriminated subgroups of patients stratified by World
Health Organization functional class (ANOVA F51.73; p,0.001).
The emPHasis-10 is a short questionnaire for assessing HRQoL in pulmonary arterial hypertension. It has
excellent measurement properties and is sensitive to differences in relevant clinical parameters. It is freely
available for clinical and academic use.
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Introduction
Pulmonary hypertension (PH) has many causes, and is a debilitating and progressive condition that can
affect people of any age and shortens life expectancy [1, 2]. It ranges from severe elevations of pressure, seen
in the context of pulmonary arterial hypertension (PAH), for which drug therapies are available, and
chronic thromboembolic PH (CTEPH), which may be cured by surgery, to relatively mild elevations of
pressure seen in the setting of respiratory and cardiac disease, where treatment is principally aimed at the
underlying condition [3].
PH is characterised by breathlessness, decreased exercise tolerance, psychological distress and lack of energy
and fatigue, resulting in a reduced health-related quality of life (HRQoL) [4–7]. As there is no cure, except
in selected patients with CTEPH, current management strategies aim to prolong survival, alleviate
symptoms and improve HRQoL. Given the central importance of HRQoL as a goal of therapy, a tool
capable of accurately quantifying this in both the clinical and trial environments would be highly desirable.
The routine collection of valid and reliable HRQoL data necessitates the availability of a short, simple,
patient-reported outcome to measure the impact that PH has on patients’ lives. Available patient-reported
outcomes frequently used in PH are often multi-dimensional and include the Cambridge Pulmonary
Hypertension Outcome Survey (CAMPHOR) [8], medical outcome study 36-Item Short Form [9], the
Nottingham Health Profile [10] and the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
[11]. The CAMPHOR is the only currently available PH-specific questionnaire and has been validated in
many countries to account for differences in language and culture [12–14]. Whilst these tools have
demonstrated validity and reliability for use in a research context [15, 16], they have limited clinical utility.
In addition, the multi-dimensional nature of a number of these tools makes the weighting process more
complex in routine clinical practice.
The aim of this multicentre study was to develop and assess the validity of an easily and rapidly
administered, simple-to-score and interpret, disease-specific questionnaire to assess HRQoL in a large
population of patients with PH, with the aim of developing a tool to use in the clinic to assess patients with
PAH and CTEPH.
Methods
The study was approved by the NRES Committee East of England (Hertfordshire, UK; 11/EE/0345), Mater
Misericordiae University Hospital (Dublin, Ireland; 1/378/1493), and the University of Manchester
(Manchester, UK). Patients provided written informed consent prior to study entry. Patients were recruited
from nationally designated specialist PH centres in the UK and Ireland, and were approached at the time of
their routine clinic visit or identified from the database of the Pulmonary Hypertension Association UK
(PHA-UK).
Inclusion criteria required a confirmed diagnosis of PH with a mean pulmonary artery pressure (PAP) of
o25 mmHg at cardiac catheterisation and required detailed assessment to allow accurate classification of
PH as per international guidelines [17]. Exclusion criteria included age ,18 years and a history of previous
successful pulmonary endarterectomy with normalisation of PAP.
Time from diagnosis was taken as time from right heart catheterisation unless the patient had congenital
heart disease, in which case time of diagnosis was taken as when the patient was diagnosed at the PH referral
centre as having PH. Targeted pulmonary vascular therapies were recorded at the time of questionnaire
completion. The 6-min walk distance (6MWD) or incremental shuttle walking test (ISWT) and World Health
Organization (WHO) functional class at the time of administration of the questionnaires were recorded.
Stage 1: item generation for inclusion in questionnaire
A qualitative study was conducted with 30 patients to explore the concept of HRQoL and their experience
of living with PH. Five of these patients also conducted self-videoing for a minimum of 5–10 min every day
for a total of 7 days. Participants were free to record any aspects of living with PH that was important to
them. Following the extraction of a draft item list, cognitive debriefing interviewing was employed [18] with
14 patients and two family members to ensure that all items were clear and easy to understand. Items were
presented to patients as a semantic differential six-point scale (0–5), anchored at each end by contrasting
adjectives. The draft item list and scaling range was reviewed by clinical experts for clinical relevance.
Stage 2: item reduction
Stage 2 involved the administration of the draft item list to patients with PH. We also collected participants’
WHO functional class, 6MWD (or ISWT) and demographic details at the time of enrolment in the study.
All patients were also requested to complete the 32-item list and the following questionnaires. 1) The
MLHFQ modified for PH is a modified version [19] of the original MLHFQ [11]. The MLHFQ-modified
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for PH has been found to be highly reproducible and demonstrated internal consistency and reliability, and
moderately good validity comparable with the values found with the CAMPHOR [20]. 2) Dyspnoea-12 (D-12)
consists of 12 items that reflect the physical perception and emotional effects of dyspnoea and has been
validated for use in PH [21, 22]. The instrument uses simple summation scoring to yield scores from 0–36, with
higher scores corresponding to greater impairment. 3) The Hospital Anxiety and Depression scale (HAD)
assesses psychological distress (seven items for anxiety with a score of 0–21, and seven items for depression with
a score of 0 –21; higher scores indicate greater emotional distress) [23].
Statistical analyses
Item reduction process
A hierarchical approach to item reduction was used followed by the application of Rasch analysis [24, 25].
The aim was to develop a uni-dimensional instrument that captured a wide range of PH experiences using
the least number of items required. The process of identifying items for potential deletion was iterative and
included items with .25% missing responses and items that demonstrated significant age or sex bias
(p,0.05). To remove the least discriminative descriptors, items demonstrating floor (.25% endorsement)
or ceiling effects (.25% endorsement) were removed. Items were also marked for potential deletion if they
demonstrated high item–item correlations (r.0.7) and low item–total correlations (r,0.3) [26].
Items that survived hierarchical reduction were scrutinised with a Rasch uni-dimensional model
(RUMM2030; www.rummlab.com). Rasch models provide a template for testing how well each item
contributes to the concept being measured [24, 27].
Individual item fit was assessed by examining the residual and Chi-squared fit statistic for each item (item
residual ¡2.5 and Chi-squared p-value .0.05) [27]. Items with the worst model fit were removed whilst
ensuring that the balance of retained items and content validity for the total item-set was retained. The
overall fit of the final item set was determined by examining the person item trait interaction Chi-squared
statistic, where a nonsignificant p-value (.0.05) indicates fit to the model [27]. See the online
supplementary material for details.
Stage 3: preliminary reliability and validity of the final item list
We tested the preliminary reliability and validity of the final item set using the same data set as in stage 2.
Internal consistency was tested using Cronbach’s a, for which values from 0.7–0.9 are acceptable [28].
Concurrent validity was assessed by evaluating correlations between the newly developed questionnaire and
the MLHFQ-modified for PH, D-12, HAD and 6MWD. 66 patients attending the Sheffield Pulmonary
Vascular Disease Unit (Sheffield, UK) who performed the ISWT did not perform a 6MWD and were excluded
from this part of the analysis. Associations with WHO functional class were calculated using ANOVA.
Test–retest reliability of the finalised item list was tested in a different group of patients, using a postal
survey sent to members of PHA-UK. Participants were sent two copies of the final item list to complete
7 days apart. Each copy of the questionnaire was placed in a separate sealed envelope clearly marked with
the date for completion (day 0 and day 7, respectively), and participants received written and telephone
directions for completion. Test–retest reliability was tested using intraclass correlation coefficient for which
values .0.7 indicated good reliability [29].
Results
Stage 1: item generation for questionnaire
30 patients (table 1) participated in the qualitative interview work that yielded a preliminary list of 32 items.
Items covered breathlessness, activity and social limitations, lack of energy, emotional issues, and treatment-
related issues. Cognitive interviewing with 14 patients and two family carers resulted in only minor
adjustments, and participants indicated that the items and response scale used were relevant and easy to
understand. PH clinicians confirmed the clinical relevance of the draft instrument.
Stage 2: item reduction
A total of 226 patients with PH (mean age 55¡14 years; 69% female) participated in stage 2 (table 2).
A complete summary of the item reduction can be found in the online supplementary material. The full
scaling range (0–5) for all 32 items was used (mean item responses ranged from 2.04¡1.5 for ‘‘being
breathlessness never interrupts my conversations’’ to 3.88¡1.3 for ‘‘when I walk up one flight of stairs I am
not breathless’’). All items had ,5% missing responses. Sex bias was significant in two items (one relating
to feeling ‘‘anxious’’ and the other to feeling ‘‘unattractive’’ because of PH), and age bias was significant in
three items; all five of these biased items were removed. Three items demonstrated a high degree of floor
effects (25–42%) and four items demonstrated a high degree of ceiling effects (26–30%); these seven items
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were removed. The item ‘‘walking up a flight of stairs makes me breathless’’ demonstrated a ceiling effect
(38%); however, this item had strong face validity during the item generation stage and was retained to
enable further scrutiny with Rasch analysis.
Item–item correlations and item–total correlations were assessed with the remaining 20 items. Eight items
were marked for possible removal due to high item-to-item correlations. Each of these items correlated with
more than one other item. Based on the frequency of an item’s high correlation with other items and our
previously conducted qualitative work, four of these items were removed at this stage, thus ensuring that a
balance between statistical significance and face validity was maintained. One item (‘‘I feel dizzy or
lightheaded’’) was removed due to a low item–total correlation.
Following the above tests, 17 items were deleted with the remaining 15 items entered into RUMM2030 for
Rasch analysis. During the iterative process of analysing the 15 items, five items were removed to achieve an
overall fit to the uni-dimensional Rasch model. This resulted in a 10-item solution demonstrating a good
Rasch model fit for individual items (see online supplementary material) and the 10 items in aggregate
(Chi-squared 16.2, p50.7). There was a good distribution of the item scores across the severity scale (fig. 1).
The 10 items form the emPHasis-10 with a total score range from 0 to 50 (fig. 2).
Stage 3: preliminary reliability and validity
emPHasis-10 demonstrated excellent internal reliability (Chronbach’s a50.9). 33 patients completed the test–
retest study and emPHasis-10 demonstrated good stability over time (intraclass correlation coefficient 0.95).
The emPHasis-10 demonstrated excellent concurrent validity with related patient reported outcome
measures including the MLHFQ-modified for PH (r50.61), HAD total (r50.77) and D-12 (r50.74) (all
p,0.001). There was a moderate correlation between the emPHasis-10 and 6MWD (r5 -0.40, p,0.001).
emPHasis-10 scores discriminated subgroups of patients stratified on WHO functional class II and III
(mean difference 10.9, 95% CI 7.3–14.5; p,0.001) (fig. 3). There were insufficient numbers of patients in
WHO functional class I and IV to draw any conclusive results.
Discussion
We have developed emPHasis-10, a rapidly administered, simple-to-score, disease-specific questionnaire to
assess HRQoL in PH. The final 10 items are formatted as a semantic six-point differential scale, a format
that has previously proven to be easy to administer and easy for patients to complete in the clinical setting [30].
TABLE 1 Participant characteristics: qualitative phase
Subjects 30
Females/males 18/12
Age years 56.3¡38 (26–80)
Aetiology of PH
Group 1: PAH
Idiopathic 12
Connective tissue disease 7
Congenital heart disease 5
Heritable 1
Portal hypertension 1
Drugs/toxins 1
Group 3: owing to respiratory disease in PH lung 1
Group 4: CTEPH 2
Time since PAH diagnosis years
,1 2
1 to ,3 2
3 to ,5 7
5 to ,10 12
.10 7
WHO functional class
I 0
II 9
III 19
IV 2
Data are presented as n or mean¡ SD (range). PH: pulmonary hypertension; PAH: pulmonary arterial
hypertension; CTEPH: chronic thromboembolic PH; WHO: World Health Organization.
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We have demonstrated that emPHasis-10 scores correlate strongly with measures of HRQoL, dyspnoea and
psychological distress. Although the emPHasis-10 has primarily been developed for evaluative purposes, this
study shows that the emPHasis-10 also has strong discriminative measurement properties according to WHO
functional class; emPHasis-10 scores increased significantly as functional class declined. The performance
characteristics of emPHasis-10 support the validity of this tool for assessing the impact of PH on the lives of
patients with PAH.
Important components of the impact of PH are covered in emPHasis-10 including breathlessness, fatigue
and lack of energy, social restrictions, and concerns regarding effects on patient’s significant others, such as
family and friends [4–7]. Despite this, the emPHasis-10 fits a uni-dimensional model where each question
TABLE 2 Participant characteristics: item reduction phase
Patients n 226
Females 157 (70)
Age years 55.6¡14
Aetiology of PH
Group 1: PAH
Idiopathic 89 (40)
Congenital heart disease 50 (22)
Connective tissue disease 43 (19)
Heritable 3 (1)
Portal hypertension 1 (0.5)
Group 2: PH left heart disease 1 (0.5)
Group 3: PH lung 1 (0.5)
Group 4: CTEPH 36 (16)
Group 5: neurofibromatosis and sarcoidosis 2 (1)
PH therapy
Monotherapy 125 (55)
Dual therapy 78 (35)
Triple therapy 11 (5)
Not recorded 12 (5)
Route
Inhaled iloprost 20 (9)
i.v. iloprost 8 (4)
i.v. treprostinil 5 (2)
i.v. epoprostenol 4 (2)
Continuous or as needed oxygen use 87 (38)
6MWD m# 336¡130
Employment status
Full-time work 25 (11)
Part-time work 31 (14)
Student 2 (1)
Unemployed/retired 168 (74)
WHO functional class
I 3 (1)
II 73 (32)
III 115 (51)
IV 34 (15)
MLHFQ modified for PH 47.8¡25
Hospital Anxiety and Depression scale
Total 13.3¡7.5
Anxiety 6.9¡4.4
Depression 6.3¡3.9
Dyspnoea-12 questionnaire
Total 12.8¡9.8
Physical 8.5¡5.8
Affective 4.4¡4.6
Data are presented as n (%) or mean¡ SD, unless otherwise stated. PH: pulmonary hypertension; PAH:
pulmonary arterial hypertension; CTEPH: chronic thromboembolic PH; 6MWD: 6-min walk distance; WHO:
World Health Organization; MLHFQ: Minnesota Living with Heart Failure Questionnaire. #: n598, patients
attending the Sheffield Pulmonary Vascular Disease Unit, Sheffield, UK (n566) underwent exercise testing with
the incremental shuttle walking test and did not perform the 6MWD.
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FIGURE 1 Distribution of a) patients and b) items based on Rasch logit locations showing the distributions of patient
health-related quality of life severity and item severity (locations) along the same linear scale measured in logits. Most
items are located between -2 and +2 logits. Total n5226, mean¡SD 0.200¡1.334.
FIGURE 2 The final emPHasis-10 questionnaire. The Pulmonary Hypertension Association UK (Rotherham, UK) intends
to make this questionnaire free to use by both the clinical and academic communities. It can be downloaded free of charge
from the Pulmonary Hypertension Association UK website (www.phassociation.uk.com) and reproduced without cost
for clinical and academic use. Different language versions will be made available in due course. Reproduced with
permission from the Pulmonary Hypertension Association UK.
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carries a similar weighting. Many existing HRQoL instruments are multidimensional, comprising separately
scored sub-domains that are often lengthy with complex scoring algorithms. A concern with many
multidimensional instruments is the reporting of a total HRQoL score when the totality of its parts might
not necessarily provide a valid overall score of HRQoL [26]. Our primary objective was to develop
an overall measure of PH HRQoL with a simple scoring system that does not require complex analysis
and interpretation.
In developing this instrument we used Rasch modelling to facilitate the development of a questionnaire that
provides measurement of HRQoL using a parsimonious collection of items that form a uni-dimensional
measure. HRQoL is generally acknowledged to be a multidimensional construct. The emPHasis-10 is
compatible with this view since it contains items that cover a range of experiences (e.g. energy,
breathlessness, social confidence and independence). The 10 items contribute reliably to the measurement
of HRQoL in PH. To do this, we required all items to fit a uni-dimensional model whereby the underlying
trait (i.e. HRQoL) has a single dimension on which all of the test items rely. This process may have excluded
items that may have behaved differently with different measurement properties. Our approach created a
pragmatic instrument with clinical utility.
There are a number of limitations in this study. The population studied had various forms of PH and are
representative of the typical patients under chronic follow-up in a UK PH centre. The vast majority had
PAH, where we feel this questionnaire is likely to have most value. Further studies need to be performed in
other important forms of PH such as CTEPH, given the relatively small numbers in this group. The
questionnaire is not currently recommended for use in other forms of PH such as PH owing to left heart
disease or respiratory disease, given the small number of patients included in this study. The patients who
were interviewed were at different points on the illness trajectory with many having relatively long standing
disease and it is likely that the duration of disease will impact on HRQoL. The current study presents cross-
sectional data; a prospective longitudinal study would be required to test the sensitivity of the instrument to
change overtime. We used data from the item reduction stage (stage 2) to test concurrent validity of the
emPHasis-10 with other relevant outcomes. These preliminary results require subsequent validation in a
separate study. We have compared emPHasis-10 with a number of other questionnaires but not to
CAMPHOR; unfortunately, at the time this study was conducted permission to use CAMPHOR was
declined. Currently, emPHasis-10 is only available in English but the PHA-UK is in the process of making it
available in a number of different languages.
In conclusion, the emPHasis-10 is a short, simple questionnaire for assessing HRQoL in PH. It has excellent
measurement properties and construct validity, and is sensitive to differences in clinical parameters. Further
work is required to evaluate its value in routine clinical practice and to assess the impact of treatment
interventions in various form of PH. A number of HRQoL questionnaires are not freely available and
various copyright laws preclude their use by both clinicians and academics. The PHA-UK has funded this
study with the specific intention of making emPHasis-10 freely available for clinical and academic use.
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